Condition P04

Children and adolescents with type 2 diabetes

Participants aged 10 to 17 years with type 2 diabetes.

6 randomized trials; 9 fitted analyses across 10 outcomes.

All outcomes

Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.

HbA1c changeprimary

O01

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 12 to 40 (target week 26)	Not stated by the trials	Doses of a drug pooled (part 2)	2	3	Network meta-analysis
weeks 12 to 40 (target week 26)	Not stated by the trials	Each dose separately (part 3)	1	2	Descriptive only
weeks 12 to 40 (target week 26)	Not stated by the trials	Each dose separately (part 2)	1	2	Descriptive only
weeks 12 to 40 (target week 26)	Treatment policy	Each dose separately	1	2	Descriptive only
weeks 12 to 40 (target week 26)	Treatment policy	Doses of a drug pooled	1	2	Descriptive only
weeks 40 to 64 (target week 52)	Treatment policy	Each dose separately	1	2	Descriptive only
weeks 40 to 64 (target week 52)	Treatment policy	Doses of a drug pooled	1	2	Descriptive only
weeks 12 to 40 (target week 26)	Hypothetical (as if everyone stayed on treatment)	Each dose separately	1	2	Descriptive only
weeks 12 to 40 (target week 26)	Hypothetical (as if everyone stayed on treatment)	Doses of a drug pooled	1	2	Descriptive only
weeks 12 to 40 (target week 26)	Not stated by the trials	Doses of a drug pooled	1	2	Descriptive only
weeks 12 to 40 (target week 26)	Not stated by the trials	Each dose separately	1	3	Descriptive only

Level 2 or 3 hypoglycemia (participants)primary

O04

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	2	4	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	2	3	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately (part 2)	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled (part 2)	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Serious adverse events

O25

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	6	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	4	6	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	1	2	Descriptive only

Discontinuation due to adverse events

O26

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	2	3	Descriptive only
longest follow-up	Recorded harms	Each dose separately	2	3	Descriptive only

Nausea

O27A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	6	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	4	6	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	1	2	Descriptive only

Vomiting

O27B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	5	6	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	4	6	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	1	2	Descriptive only

Diarrhea

O27C

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	4	5	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately	3	5	Network meta-analysis
longest follow-up	Recorded harms	Each dose separately (part 2)	1	2	Descriptive only

Constipation

O27D

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Acute pancreatitis

O29

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	3	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Death by suicide

O35B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only